급성 골수성 백혈병에서의 병적 비장파열 1 예

이순남,한운섭,경난호,성연아,손현주,박응범,임양희,박이갑 대한내과학회 1987 대한내과학회지 Vol.33 No.3

Spontaneous splenic rupture is a rare complication of hematologic malignancies. A case of spontaneous rupture of spleen in 31-year-old man with acute myelacytic leukemia, M2 is presented, Splenectomy was carried out successfully and he is alive in remission status without any complication.

장티푸스에 동반된 Hypoplastic Anemia의 1예

이순남,경난호 梨花女子大學校 醫科大學 醫科學硏究所 1983 EMJ (Ewha medical journal) Vol.6 No.3

The authors experienced a 29 year old female patient with hypoplastic anemia during her illness of typhoid fever. Because that is very rare and unreported, we are reporting this patient. She was promptly recovered from hypoplastic anemia with antibiotics for typhoid fever.

국소진행된 비소세포 폐암의 선행화학요법후 방사선 병용요법 : 장기추적 결과 Long Term Results

이순남 梨花女子大學校 醫科大學 醫科學硏究所 1994 EMJ (Ewha medical journal) Vol.17 No.4

To evaluate the long term results of sequential neoadjuvant chemotherapy followed by radiotherapy in locally advanced non small ciell lung cancer(NSCLC), 32 patients with stage Ⅲ NSCLC were atudied. Neoadjuvanjt chemotherapy was performed with 2-3 cycles of cisplatin containing combination at the interval of 3-4 weeks, and then radiotherapy to and primary tumor, mediastinum and both supaclavicular lymph nodes was followed. The results were as follows: 1) After neoadjuvant chemotherapy, partial remission(PR) rate was 59.4% without complete remission(CR). At completion of radiotherapy, CR rate was 28.1%, PR rate 50.0% and overall response rate was 78.1%. 2) The median survival of all patients was 14.4 months, for stage ⅢA NSCLC patients was 22 months compared to 11.4 month in stage ⅢB NSCLC patients without significance. For responder of neoadjuvant chemotherapy, median survival was 16.6 months, and 9.3 months for the non responder(p<0,05). Median survival of responders at completion of chemotherapy was 26.8 months at the rangd of 4-48 months. Overall survival rate at 2 year was 27.1% and continued plateau till 50 months without late relapse. 3) The acute toxicities were tolerable in all patients and not fatal, but late complications of three restricitive pneumonitis and one cough induced syncopal attack compromise the quality of life among the 8 long term survivors who lived over 2 years. 4) The relapse rate was 58.1%(18 out of 31 cases) and the pattern of relapse was local in 14 cases(45.2%), systemic in 3 cases(9.7%) and local plus systemic in 1 case(3.2%). The sites of systemic relapse were brain in 3 cases and brain combined with bone in 1 case. In conclusion, sequential neoadjuvant chemotherapy and radiotherapy can prolong the survival and diminish the systemic relapse in locally advanced non small cell lung cancer patients but local failure was the main problem in these patients. To enhance the local control, other trials such as concurrent chemoradiotherapy, hyperfractionated radiotherapy combined with developing more effective new chemotherapeutic agents and combined regimens should be further investigated.

고기질도 소비자 위주로$\cdots$

이순남 대한양계협회 1987 월간 양계 Vol.19 No.9

쥐의 Adriamycin에 의한 점막염에 대한 Sucralfate의 예방효과

이순남 梨花女子大學校 醫科大學 醫科學硏究所 1996 EMJ (Ewha medical journal) Vol.19 No.3

연구목적 : 항암제 치료에 의한 점막염의 예방에 경구 sucral-fate의 예방효과에 대한 이견이 있어 이를 임상응용하기 전에 쥐에서 adriamycin 투여 후 점막염을 유발하고 sucralfate를 경구투여하여 그 예방효과를 확인하여 임상응용에 이용하고자 실험을 수행하였다. 연구방법 : 예비실험에는 250~300gm 의 Sprague Dawley쥐를 10mg/kg의 adriamycin을 복강내 주사하고 2일간격으로 4마리씩 12일까지 희상시켜 관찰하였다. 본 실험에서는 각 군당 4마리씩 adriamycin 10mg/kg 단독투여군(제1군), sucralfate 100mg/kg/day(제2군), 50mg/kg/day(제3군), 병용투여군과, sucral-fate 100mg/kg/day(제4군), 50mg/kg/day(제5군) 단독투여군으로 하고 제 10일에 희생시켜 육안 및 he-matoxilin과 eosin 염색 후 광학현미경으로 관찰하였다. 연구결과 : 제10일에 adriamycin에 의한 점막염이 관찰에 가장 적당하였다. 경구 sucralfate의 병용투여는 10mg/kg/day 또는 50mg/kg/day에서 모두 점막염 예방효과가 있었고, sulcrafate 단독투여에 따른 부작용은 없었다. 결론 : 경구 sucralfate의 투여는 쥐에서 adriamycin에 의해 유발된 점막염의 예방에 효과적이었으며 이는 암환자에서 항암제치료나 방사선치료에 의한 잠막염의 예방을 위한 sucralfate의 임상시험도 가능할 것으로 생각된다. Objective : Mucositis is a threatening complication of chemotherapy and/or radiotherapy. To evaluate the prophylactic effect of sucralfate on adriamycin induced mucositis in the rat for the basis of application of sucralfate in cnacer patients, the experiments were performed. Methods : In preliminary study 250 ~ 300gm Sprague Dawley rats were injected 10mg/kg of adriamycin intraperitoneally and 4 rats were dissected every other day till 12 days. The sucralfate were applied per os with aqueous portion of 100mg/kg and 50 mg/kg just after intraperitoneal injection of adriamycin 10mg/kg. On Day 10, 4 rats on each group were dissected and oral, esophageal and gastric mucosa were obtained and histologocally examined. Results : On day 10, adriamycin induced mucositis was most severe. The application of sucralfate significantly lessened the adriamycin induced mucositis was most severe. The application of sucralfate significantly lessened the adriamycin induced mucositis compared to that of control without sucralfate on the dose of 100mg/kg or 50mg/kg, respectively. And there was no ad-verse effect by sucralfate itself. Conclusion : Oral sucralfate could prevent the adriamycin induced mucositis in the rats without any adverse effect. This result supports that sucralfate can be used in the clinical trials on chemotherapy and/or radiotherapy induced mucositis for prophylaxis.

소세포폐암의 임상적 관찰

이순남 梨花女子大學校 醫科大學 醫科學硏究所 1990 EMJ (Ewha medical journal) Vol.13 No.4

Twenty nine patients with small cell lung cancer patients has been studied from January 1986 to September 1990. In 14 limited disease patients, combination chemotherapy combined with radiotherapy to primary lung, mediastinum, supraclavicular lymph nodes and prophylatic whole brain irradiation was performed. Fifteen extensive disease patients were treated combination chemotherapy alone. The results obtained were as follows : 1) Coughing, dyspnea and chest pain were frequent symptomes in the order of frequency. Syndrome of inappropriate antidiuretic hormone secretion and Eaton-Lambert syndrome were observed in 20.7% and 19.0% respectively. 2) A 92.8% overall response rate and 50.0% overall complete remission rate in limited disease and 53.0% overall reponse rate width 40.0% complete remission rate in limited disease and 53.0% overall reponse rate with 40.0% complete remission rate in extensive disease were achieved. Overall response rate of limited disease was higher than that of extensive disease. 3) Overall median survival was 10.9 months and 11.1 months in limited diease and 8.4 months in extensive diease were obtained. Overall median survival of complete responder was 11.7 months, that was longer than 6.0 months of partial responders. 4) The treatment toxicities were mainly nausea, vomiting and alopecia but fatal one episode or arganulocytosid was experienced. Further trials and new therapeutic plans are must be set to improve therapeutic efficary and minimize toxicities.

악성종양 환자에서 A. Port Implantation의 유용성과 합병증

이순남,김광호 梨花女子大學校 醫科大學 醫科學硏究所 1993 EMJ (Ewha medical journal) Vol.16 No.4

Reliable venous access is increasing serious problem in cancer chemotherapy Patients. Thiry six implantable second generation catheter system(A. Port) were placed subcutaneouslyin 35 patients with cancer. A Port were in place f3r an ave.age of 158 days(range 10-731^+ days). Complicationsincluded infections in 3 cases, thrombosis in 1 case, skin laceration in 1 case and pneurnothoraxin 1 case. Five ports were removed due to complication. One pneumothorax was managedconservatively; It is concluded that A. Port implantation constitute a safe and convenient access with alow rate of complication for long term intravenous chemotherapy in cancer patients.

혈액종양질환 환자에서의 염색체 이상 : Analysis of 42 Cases

이순남 梨花女子大學校 醫科大學 醫科學硏究所 1992 EMJ (Ewha medical journal) Vol.15 No.4

With development of new technology such as handing technique and high resolution banding technique, cytogenetic examination has been utilized greatly in diagnosis and treatment of patients with hemato-oncologic diseases. Forty two patients with newly diagnosed and previously untreated hemato-oncologic diseases were examined for chromosomal abnormalities which included 11 cases of acute myelogenous leukemia(AML). 7 cases of acute lymphoblastic leukemia (ALL) and myelodyspalstic syndrome (MDS) each, 6 cases of chronic myelogenous leukemia (CML). 5 cases of other myelolproliferative disorders(MPD). 4 cases of non-Hodgkin's lymphoma(MHL). and 1 case each of aplastic anemia(AA) and malignant schwannoma(MS). Two cases of AML(18.2%) showed 45 XO and aneuploidy. Four cases of ALL(55.5%) showed chromosomal abnormalities : 3 cases with Philadelphia chromosome and 1 case with 45 XO. Only one case of MDS(14.3%) showed trisomy 8 and none of 3 cases which were converted to AML showed chromosomal abnormalities. Five cases of CML(83.3%) showed Philadelphia chromosome. Chromosomal abnormalities were not noted in cases of MPD, MHL, AA and MS. Collective studies of chromosomal abnormalities in hemato-onclologic diseases should be investigated further.

진행성 비소세포폐암 환자의 Ifosfamide, Etoposide와 Cisplatin(IEP) 복합화학요법

이순남 梨花女子大學校 醫科大學 醫科學硏究所 1993 EMJ (Ewha medical journal) Vol.16 No.4

To evaluste the efficacy and toxicity of IEP chemotherapy in locally advanced and metastaticnon-small cell lung cancer, nineteen previously untreated patients with non-small cell lungcancer were studied. Patients received ifosfamide 1000mg/m^2 with mesna, 20% of ifosfamide dose at 0,4, 8 hoursafter ifosfamide, etoposide 100mg/m^2, and cisplatin 20mg/m^2 with full hydration and mannitoldiuresis intravenously on days 1-3 every 4 weeks. Eighteen male and one female, two stage ⅢA, 10 stage ⅢB and 7 stage Ⅳ patients havebeen treated. The response rate of IEP was 26% with no complete remission, 53% of stable disease, and23% of progressive diasease. The overall median survival was not reaced yet and 20 month survival rate was 51.4%, The duration of remission was at the range of 4^+ to 40 weeks. The toxicities were alopecia (100%), nausea and vomiting(47%), leukopenia(14%), infection(6%), renal dysfunction(6%) and oral mucositis(5%). This phase Ⅱ study of IEP in advanced non-small cell lung cancer is not superior to another combinatiori regimens in terms of response but toxicity was tolerable. Other new chemothera-peutic drugs and newer trials should be developed further.

[당선소감] 희망과 소망을 담은 두레박질

이순남 아동문학평론사 2011 兒童文學評論 Vol.36 No.4